Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.

Stefan D Anker,Muhammad Shahzeb Khan,Javed Butler,Anne Pernille Ofstad,Barbara Peil,Egon Pfarr,Wolfram Doehner,Naveed Sattar,Andrew J S Coats,Gerasimos Filippatos,João Pedro Ferreira,Faiez Zannad,Stuart Pocock,Milton Packer

European journal of heart failure（2023）

引用 13|浏览29

暂无评分

摘要

The benefits of empagliflozin versus placebo were consistently present across all BMI categories in HFrEF patients. Weight loss was associated with higher risk of all-cause mortality, regardless of treatment group.

查看译文

关键词

Body mass index,Empagliflozin,Heart failure,Weight loss

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要